Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims referencing brand and generic naming, and presence of diazepam and strength on pharmacy labels are supported by the provided label sections. Several claims about generics, cross-manufacturer branding, and generic equivalence are not addressed in the labeling and are therefore unsupported. No direct contradictions to the labeling are present.
Category Scores
Accurate Statements
Valium is the brand name for diazepam.
PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
The generic name you’ll see on prescriptions or packaging is diazepam.
PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
Diazepam (active ingredient) is shown on a pharmacy label.
PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label; DESCRIPTION
Diazepam tablets (or the relevant formulation) are shown on a pharmacy label.
PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
The strength (mg) is shown on a pharmacy label.
PRINCIPAL DISPLAY PANEL - 2 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
Valium tablets contain 2 mg, 5 mg or 10 mg diazepam as described in the DESCRIPTION section.
DESCRIPTION
Unsupported Statements
There aren’t separate generic names for Valium itself.
Label does not provide information about generic naming conventions beyond the brand/generic pairing; claim is not supported by the provided labeling.
The same active ingredient—diazepam—is marketed under different manufacturer or company names.
Label shows Roche as the listed manufacturer for Valium products, but the claim about multiple manufacturers across brands is not supported by the provided labeling.
The usual drug form/strength accompanies diazepam in generics (for example, “diazepam tablets” with a given mg dose).
Label information confirms specific tablet strengths but does not address generic naming conventions or whether generics always present in the same form/strength; thus the claim is not supported by the labeling.
In most places, if diazepam is available generically, pharmacists can usually dispense a generic equivalent to Valium.
No information about generic dispensing practices or interchangeability is provided in the labeling.
They are the same active drug (diazepam).
While labeling shows Valium (brand) and diazepam (active ingredient), the claim about equivalence across all contexts is not explicitly addressed in the provided label content.
They typically have the same form and strength.
The label confirms multiple strengths (2 mg, 5 mg, 10 mg) but does not assert universal form/strength parity across all products; this is not explicitly supported by the provided labeling.
Contradictions
Important Omissions
Approved indications/usage (indications) for Valium are not evaluated or mentioned in the provided claims.
Importance:
High
Detailed administration instructions and safety-related prescribing information (e.g., dosing guidance, contraindications, boxed warnings, and interactions) are not addressed in the claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on branding/labeling assertions (brand/generic name and presence of diazepam on labels) with no safety-related claims or dosing instructions evaluated.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
If evaluating broader regulatory labeling claims, include explicit statements about indications, contraindications, warnings, and administration guidance. Consider adding clarifications about generic naming conventions and cross-manufacturer generic availability if those topics are within scope.